查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1620846

色素性視網膜炎市場：按類型、產品、最終用途分類 - 2025-2030 年全球預測

Retinitis Pigmentosa Market by Type (Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, X-linked Retinitis Pigmentosa), Offering (Diagnosis, Treatment), End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年色素性視網膜炎市值為98.5億美元，預計到2024年將達到106.6億美元，複合年成長率為9.02%，預計到2030年將達到180.4億美元。

色素性視網膜炎（RP）是一組罕見的遺傳性疾病，其特徵是視網膜細胞的破壞和喪失，通常導致視力障礙和失明。該市場包括治療藥物、輔助技術、基因測試以及用於該疾病管理和診斷的諮詢服務。該領域取得進展的需要源於對有效治療方法的需要，因為目前的治療方法主要是姑息性的。應用範圍從基因治療和視網膜植入等藥物干預到技術先進的視覺輔助工具。最終用途範圍包括積極參與這些解決方案部署和開發的醫院、眼科診所和研究機構。

主要市場統計
基準年[2023] 98.5億美元
預計年份 [2024] 106.6億美元
預測年份 [2030] 180.4億美元
複合年成長率（%） 9.02%

影響 RP 市場的主要成長要素包括由於診斷能力的提高、生物技術的進步以及基因研究投資的增加而導致的盛行率增加。創新治療方法的發展，例如基於 CRISPR 的基因編輯和新型藥物輸送系統，提供了巨大的潛在機會。企業應專注於策略夥伴關係和協作研究，以加快研究速度並擴大產品平臺。然而，市場成長面臨著治療成本高、認知有限和嚴格的監管障礙等挑戰，特別是在基因治療方面。

成熟的研究和開發創新領域包括基因治療、幹細胞治療和穿戴式助視器的開發。這些領域的努力可以帶來對市場狀況產生重大影響的突破。這些努力可能不僅有助於開發更好的治療方法，而且有助於增強輔助技術，提高患者的生活品質。

儘管 RP 市場高度專業且有些分散，但對研發和技術的密集投資可以創造巨大的成長空間。設計加強患者就診的政策，結合提高意識的教育宣傳活動，可以緩解現有的限制，進一步擴大市場機會，並促進永續的業務成長。

市場動態：快速發展的視網膜色素變性市場的關鍵市場洞察

供需的動態交互作用正在改變色素性視網膜炎市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 影響視網膜的罕見眼科疾病的全球盛行率不斷上升
    • 越來越重視基因治療和個人化醫療
  • 市場限制因素
    • 色素性視網膜炎必要治療的可近性和可負擔性
  • 市場機會
    • 政府支持核准新開發的治療色素性視網膜炎的藥物
    • 視網膜色素變性治療和診斷的持續進展
  • 市場挑戰
    • 對疾病缺乏認知與誤診

波特的五力：駕馭視網膜色素變性市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解視網膜色素變性市場的外部影響

外部宏觀環境因素在塑造視網膜色素變性市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解色素性視網膜炎市場的競爭格局

色素性視網膜炎市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣視網膜色素變性市場供應商的績效評估

FPNV 定位矩陣是評估視網膜色素變性市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製視網膜色素變性市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對視網膜色素變性市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球影響視網膜的罕見眼科疾病率不斷上升
      • 越來越重視基因治療和個人化醫療
    • 抑制因素
      • 色素性視網膜炎所需治療的可近性和可負擔性
    • 機會
      • 政府支持核准新開發的治療色素性視網膜炎的藥物
      • 治療和診斷色素性視網膜炎的持續進步
    • 任務
      • 對疾病缺乏認知與誤診
  • 市場區隔分析
    • 類型：體染色體顯性遺傳性色素性視網膜炎導致色素性視網膜炎病例迅速增加
    • 最終用途：色素性視網膜炎的專科診所治療和管理的利用演變
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章色素性視網膜炎市場：依類型

  • 體染色體顯性遺傳性視網膜色素變性
  • 體染色體隱性遺傳色素性視網膜炎
  • X連鎖色素性視網膜炎

第7章視網膜色素變性市場：透過提供

  • 診斷
  • 治療

第 8 章色素性視網膜炎市場：依最終用途

  • 居家護理
  • 醫院
  • 專科診所

第9章美洲視網膜色素變性市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太視網膜色素變性市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲視網膜色素變性市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • jCyte 的 jCell 療法進入色素性視網膜炎的 3 期試驗
    • 楊森從 Meira GTx 獲得開創性 XLRP 基因療法的權利，以加速視網膜疾病的進展
    • RD 基金會支持 NVAsc 視網膜治療的突破性進展
  • 戰略分析和建議

公司名單

  • 4D Molecular Therapeutics, Inc.
  • Astellas Pharma Inc.
  • Beacon Therapeutics Limited
  • BIOGEN INC.
  • Clino Corporation
  • Coave Therapeutics SA
  • Editas Medicine, Inc.
  • GENSIGHT BIOLOGICS
  • Genethon
  • Johnson & Johnson Services, Inc.
  • MeiraGTx Holdings PLC
  • Mimetogen Pharmaceuticals
  • Nacuity Pharmaceuticals, Inc.
  • Novartis AG
  • Orphagen Pharmaceuticals, Inc.
  • Oxford Biomedica PLC
  • Precision BioSciences, Inc.
  • ProQR Therapeutics NV
  • Sanofi SA
  • Santen Pharmaceutical Co., Ltd.
  • Spark Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • The Wyanoke Group
Product Code: MRR-7A1CEDCFE674

The Retinitis Pigmentosa Market was valued at USD 9.85 billion in 2023, expected to reach USD 10.66 billion in 2024, and is projected to grow at a CAGR of 9.02%, to USD 18.04 billion by 2030.

Retinitis Pigmentosa (RP) is a group of rare genetic disorders characterized by the breakdown and loss of cells in the retina, which often leads to vision impairment and blindness. The market scope encompasses therapeutics, assistive technologies, and genetic testing and counseling services aimed at managing and diagnosing the condition. The necessity of advancements in this field stems from the demand for effective treatments, as current therapies are primarily palliative. The application scope spans from pharmacological interventions such as gene therapies and retinal implants to technologically advanced visual aids. The end-use scope includes hospitals, eye care clinics, and research institutions that are actively involved in deploying and developing these solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 9.85 billion
Estimated Year [2024] USD 10.66 billion
Forecast Year [2030] USD 18.04 billion
CAGR (%) 9.02%

Key growth factors influencing the RP market include increasing prevalence rates due to better diagnostic capabilities, advancements in biotechnology, and rising investment in genetic research. The development of innovative treatments like CRISPR-based gene editing and novel drug delivery systems offers significant potential opportunities. Companies should focus on strategic partnerships and collaborations to accelerate research and expand their product pipelines. However, market growth faces challenges such as high treatment costs, limited awareness, and stringent regulatory hurdles, especially concerning gene therapies.

Innovative areas poised for research and development include gene therapy, stem cell therapy, and development of wearable visual aids. Engaging in these areas may lead to breakthroughs that significantly impact the market landscape. Such endeavors are likely to find traction not only in developing better therapeutic solutions but also in enhancing assistive technologies that improve the quality of life for patients.

While the RP market is highly specialized and somewhat fragmented, focused investment in R&D and technology can provide significant room for growth. Crafting policies that bolster patient access, coupled with educational campaigns to increase awareness, can mitigate existing limitations, further expanding market opportunities and contributing towards sustainable business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Retinitis Pigmentosa Market

The Retinitis Pigmentosa Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of rare eye diseases affecting retina worldwide
    • Growing emphasis on genetic therapies and personalized medicine
  • Market Restraints
    • Accessibility and affordability of treatments required for retinitis pigmentosa
  • Market Opportunities
    • Supportive government approvals for newly developed drugs to treat retinitis pigmentosa
    • Ongoing treatment and diagnostics advancements to treat retinitis pigmentosa
  • Market Challenges
    • Lack of awareness and misdiagnosis of the condition

Porter's Five Forces: A Strategic Tool for Navigating the Retinitis Pigmentosa Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Retinitis Pigmentosa Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Retinitis Pigmentosa Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Retinitis Pigmentosa Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Retinitis Pigmentosa Market

A detailed market share analysis in the Retinitis Pigmentosa Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Retinitis Pigmentosa Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Retinitis Pigmentosa Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Retinitis Pigmentosa Market

A strategic analysis of the Retinitis Pigmentosa Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Retinitis Pigmentosa Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Astellas Pharma Inc., Beacon Therapeutics Limited, BIOGEN INC., Clino Corporation, Coave Therapeutics SA, Editas Medicine, Inc., GENSIGHT BIOLOGICS, Genethon, Johnson & Johnson Services, Inc., MeiraGTx Holdings PLC, Mimetogen Pharmaceuticals, Nacuity Pharmaceuticals, Inc., Novartis AG, Orphagen Pharmaceuticals, Inc., Oxford Biomedica PLC, Precision BioSciences, Inc., ProQR Therapeutics N.V., Sanofi S.A., Santen Pharmaceutical Co., Ltd., Spark Therapeutics, Inc., Sun Pharmaceutical Industries Ltd., and The Wyanoke Group.

Market Segmentation & Coverage

This research report categorizes the Retinitis Pigmentosa Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, and X-linked Retinitis Pigmentosa.
  • Based on Offering, market is studied across Diagnosis and Treatment.
  • Based on End-use, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of rare eye diseases affecting retina worldwide
      • 5.1.1.2. Growing emphasis on genetic therapies and personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Accessibility and affordability of treatments required for retinitis pigmentosa
    • 5.1.3. Opportunities
      • 5.1.3.1. Supportive government approvals for newly developed drugs to treat retinitis pigmentosa
      • 5.1.3.2. Ongoing treatment and diagnostics advancements to treat retinitis pigmentosa
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness and misdiagnosis of the condition
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Burgeoning cases of retinitis pigmentosa due to autosomal dominant retinitis pigmentosa
    • 5.2.2. End-use: Evolving utilization of specialty clinics for the treatment and management of retinitis pigmentosa
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Retinitis Pigmentosa Market, by Type

  • 6.1. Introduction
  • 6.2. Autosomal Dominant Retinitis Pigmentosa
  • 6.3. Autosomal Recessive Retinitis Pigmentosa
  • 6.4. X-linked Retinitis Pigmentosa

7. Retinitis Pigmentosa Market, by Offering

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Treatment

8. Retinitis Pigmentosa Market, by End-use

  • 8.1. Introduction
  • 8.2. Homecare
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Retinitis Pigmentosa Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Retinitis Pigmentosa Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Retinitis Pigmentosa Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. jCyte's jCell Therapy Enters Phase 3 Trials for Retinitis Pigmentosa
    • 12.3.2. Janssen Acquires Rights to Pioneering XLRP Gene Therapy from MeiraGTx, Catalyzing Advancements in Retinal Diseases
    • 12.3.3. The RD Fund Backs NVasc's Breakthrough in Retinal Therapeutics
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4D Molecular Therapeutics, Inc.
  • 2. Astellas Pharma Inc.
  • 3. Beacon Therapeutics Limited
  • 4. BIOGEN INC.
  • 5. Clino Corporation
  • 6. Coave Therapeutics SA
  • 7. Editas Medicine, Inc.
  • 8. GENSIGHT BIOLOGICS
  • 9. Genethon
  • 10. Johnson & Johnson Services, Inc.
  • 11. MeiraGTx Holdings PLC
  • 12. Mimetogen Pharmaceuticals
  • 13. Nacuity Pharmaceuticals, Inc.
  • 14. Novartis AG
  • 15. Orphagen Pharmaceuticals, Inc.
  • 16. Oxford Biomedica PLC
  • 17. Precision BioSciences, Inc.
  • 18. ProQR Therapeutics N.V.
  • 19. Sanofi S.A.
  • 20. Santen Pharmaceutical Co., Ltd.
  • 21. Spark Therapeutics, Inc.
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. The Wyanoke Group

LIST OF FIGURES

  • FIGURE 1. RETINITIS PIGMENTOSA MARKET RESEARCH PROCESS
  • FIGURE 2. RETINITIS PIGMENTOSA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RETINITIS PIGMENTOSA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RETINITIS PIGMENTOSA MARKET DYNAMICS
  • TABLE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023